• By ICR Secretariat
  • Posted Tuesday, June 21, 2022

FDA advisers offer unanimous support to second Bluebird gene therapy


For the second time in two days, advisers to the Food and Drug Administration gave their unanimous support to an experimental gene therapy for a rare inherited disease, agreeing its benefits outweigh its risks.